CHARACTERIZATION OF MURINE COMPLEMENT RECEPTOR TYPE-2 AND ITS IMMUNOLOGICAL CROSS-REACTIVITY WITH TYPE-1 RECEPTOR

被引:76
作者
KINOSHITA, T
THYPHRONITIS, G
TSOKOS, GC
FINKELMAN, FD
HONG, KS
SAKAI, H
INOUE, K
机构
[1] NIDDKD, KIDNEY DIS SECT, BETHESDA, MD 20892 USA
[2] UNIFORMED SERV UNIV HLTH SCI, DEPT MED, BETHESDA, MD 20814 USA
关键词
B cells; Monoclonal antibodies;
D O I
10.1093/intimm/2.7.651
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously demonstrated that some mAbs prepared against mouse complement receptor type 1 (CR1) bind a 150, 000 Mr protein in addition to the 190, 000 Mr CR1 protein. We now identify the 150, 000 Mr murine protein as complement receptor type 2 (CR2), since: (I) one of the monoclonal antibodies that bind this protein Inhibits rosette formation between mouse B cells and C3d-bearing sheep erythrocytes; (II) as is known for human CR2, this protein is present on B lymphocytes but not T lymphocytes; and (iii) this protein must have affinity for C3b, since It has weak factor I cofactor activity. in addition, this protein resembles the 145, 000 Mr human CR2 molecule in size. Since four of the five mAbs that were produced by immunization with CR1 also bound CR2, and they bind to different CR1 epttopes, it seems that murine CR1 and CR2 share multiple epitopes. Injection of mice with one of the CR1- CR2 cross-reactive mAbs almost eliminated both CR1 and CR2 expression, but did not decrease B cell numbers or the expression of B cell IgM, la, or B220 antigens. in contrast, Injection of mice with a non-cross-reactlve anti-CR1 antibody only modulated CR1 expression. These antibodies should thus provide useful tools for the study of the in vivo roles of B cell complement receptors. © 1990 Oxford University Press.
引用
收藏
页码:651 / 659
页数:9
相关论文
共 43 条
[1]  
AEGERTERSHAW M, 1987, J IMMUNOL, V138, P3488
[2]   STRUCTURE AND FUNCTION OF THE COMPLEMENT RECEPTORS, CR-1 (CD35) AND CR-2 (CD21) [J].
AHEARN, JM ;
FEARON, DT .
ADVANCES IN IMMUNOLOGY, 1989, 46 :183-219
[3]   ISOLATION AND CHARACTERIZATION OF A C3B RECEPTOR-LIKE MOLECULE FROM MEMBRANES OF A HUMAN B-LYMPHOBLASTOID CELL-LINE (RAJI) [J].
BAREL, M ;
CHARRIAUT, C ;
FRADE, R .
FEBS LETTERS, 1981, 136 (01) :111-114
[4]  
BAZIN H, 1986, METHOD ENZYMOL, V121, P638
[5]   ANTI-MAC-1 SELECTIVELY INHIBITS THE MOUSE AND HUMAN TYPE 3 COMPLEMENT RECEPTOR [J].
BELLER, DI ;
SPRINGER, TA ;
SCHREIBER, RD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (04) :1000-1009
[6]   INDUCTION OF TOLERANCE BY MONOCLONAL-ANTIBODY THERAPY [J].
BENJAMIN, RJ ;
WALDMANN, H .
NATURE, 1986, 320 (6061) :449-451
[7]  
BOTTGER EC, 1987, IMMUNOL TODAY, V8, P261, DOI 10.1016/0167-5699(87)90184-8
[8]   A MONOCLONAL-ANTIBODY THAT RECOGNIZES B-CELLS AND B-CELL PRECURSORS IN MICE [J].
COFFMAN, RL ;
WEISSMAN, IL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (02) :269-279
[9]  
COLE JA, 1989, J IMMUNOL, V143, P397
[10]   IDENTIFICATION OF AN ADDITIONAL CLASS OF C3-BINDING MEMBRANE-PROTEINS OF HUMAN PERIPHERAL-BLOOD LEUKOCYTES AND CELL-LINES [J].
COLE, JL ;
HOUSLEY, GA ;
DYKMAN, TR ;
MACDERMOTT, RP ;
ATKINSON, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (03) :859-863